TLSA — Tiziana Life Sciences Ltd
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1723069 ·
Last close
$0.65
Market Cap
$82.46M
52W High
$1.90
52W Low
$0.55
ADV30
588,126
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | 11,660,000 | 3,178,000 | 14,407,000 |
| Dec 2025 | — | — | — | — | 11,495,000 | 4,010,000 | 11,443,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-175,496,000
Inventory
—
Receivables
$6,259,000
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -21,132,000 | -18,431,000 | 11,495,000 | 11,443,000 | 52,000 | -12,847,000 |
| Dec 2024 | 0 | -15,794,000 | -11,863,000 | 11,284,000 | 7,348,000 | 3,936,000 | -1,526,000 |
| Dec 2023 | 0 | -17,984,000 | -17,691,000 | 12,184,000 | 6,648,000 | 5,536,000 | -15,698,000 |
| Dec 2022 | 0 | -14,586,000 | -15,397,000 | 26,477,000 | 6,906,000 | 19,571,000 | -19,615,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLYB | Rallybio Corp | $82.32M | $15.29 | — |
| ZOMDF | Zomedica Corp. | $83.30M | $0.09 | — |
| RACC | Research Alliance Corp III | $78.68M | $10.12 | — |
| DERM | Journey Medical Corp | $86.70M | $3.90 | — |
| RVRC | Revium Rx. | $86.84M | $1.43 | — |
News headlines (Yahoo Finance, 1h cache)
Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference 2026 in London
2026-11-12 13:00 · Yahoo
Tiziana’s nasal foralumab reduces microglial activation in progressive MS trial
2026-11-09 19:46 · Yahoo
Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary
2026-11-09 18:30 · Yahoo
Tiziana Life Sciences to advance foralumab partnering talks at BIO-Europe 2026
2026-11-09 14:54 · Yahoo
Tiziana Life Sciences to Present at BIO-Europe 2026 and Host KOL Webcast
2026-11-09 12:00 · Yahoo
Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results
2026-11-05 19:00 · Yahoo
Tiziana Life Sciences reports positive phase 2a results for Intranasal Foralumab in MS
2026-11-02 14:48 · Yahoo
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
2026-11-02 12:00 · Yahoo
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
2026-10-21 11:00 · Yahoo
Tiziana completes dosing in Phase 2 Alzheimer’s trial of intranasal foralumab
2026-10-16 12:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.